The intriguing role of Rifaximin in gut barrier chronic inflammation and in the treatment of Crohn’s disease-Reference-Cited by-同舟云学术

The intriguing role of Rifaximin in gut barrier chronic inflammation and in the treatment of Crohn’s disease

Published:2018-06-03 Issue:6 Volume:27 Page:543-551
ISSN:1354-3784
Container-title:Expert Opinion on Investigational Drugs
language:en
Short-container-title:Expert Opinion on Investigational Drugs

Author:

Lopetuso Loris R.¹,Napoli Marco¹,Rizzatti Gianenrico¹,Gasbarrini Antonio¹^ORCID

Affiliation:

1. Department of Internal Medicine and Gastroenterology, Fondazione Policlinico Universitario A. Gemelli IRCCS – Università Cattolica del Sacro Cuore, Roma, Italy

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Pharmacology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/13543784.2018.1483333

Reference85 articles.

1. Gut Microbiota Modulation and Mucosal Immunity: Focus on Rifaximin

2. Role of the normal gut microbiota

3. Diversity of the Human Intestinal Microbial Flora

4. Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases

5. The Role of Antibiotics in Gut Microbiota Modulation: The Eubiotic Effects of Rifaximin

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Microbiota and IBD: Current knowledge and future perspectives;DIGEST LIVER DIS;2024

2. The role of gut microbiota in human metabolism and inflammatory diseases: a focus on elderly individuals;Annals of Microbiology;2024-01-03

3. Dual Role of Pregnane X Receptor in Nonalcoholic Fatty Liver Disease;Current Molecular Pharmacology;2023-11-17

4. Microbiota and IBD: Current knowledge and future perspectives;Digestive and Liver Disease;2023-11

5. The microbiome landscape in pediatric Crohn’s disease and therapeutic implications;Gut Microbes;2023-08-23